Drug Profile
Research programme: tyrosine kinase inhibitors - MannKind/The Leukemia & Lymphoma Society
Latest Information Update: 01 May 2012
Price :
$50
*
At a glance
- Originator MannKind Corporation; The Leukemia & Lymphoma Society
- Class
- Mechanism of Action Protein tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported T-cell lymphoma; T-cell prolymphocytic leukaemia
Most Recent Events
- 01 May 2012 No development reported for T-cell lymphoma in USA (unspecified route)
- 01 May 2012 No development reported for T-cell prolymphocytic leukaemia in USA (unspecified route)
- 05 May 2008 Early research in T-cell lymphoma in USA (unspecified route)